Using PET Scans to Improve Treatment for Esophageal Cancer
Author Information
Author(s): Lorenzen Sylvie, Gall Carl, Stange Annika, Haag Georg M, Weitz Jürgen, Haberkorn Uwe, Lordick Florian, Weichert Wilko, Abel Ulrich, Debus Jürgen, Jäger Dirk, Münter Marc W
Primary Institution: National Center for Tumor Diseases (NCT), University of Heidelberg, Germany
Hypothesis
Can PET scans predict histopathological response in patients with metabolic non-response to standard chemotherapy for esophagogastric junction adenocarcinoma?
Conclusion
The study aims to determine if changes in tumor FDG-uptake can predict histopathological response after intensified radiochemotherapy in patients who initially do not respond to chemotherapy.
Supporting Evidence
- About 40%-50% of patients do not respond metabolically to standard chemotherapy.
- Metabolic non-responders have a low histopathological response rate of only 5%.
- Early metabolic assessment can help select patients who are not benefiting from neoadjuvant chemotherapy.
Takeaway
Doctors want to see if a special scan can help them know if a cancer treatment is working early on, so they can change it if it's not helping.
Methodology
This is a prospective, non-randomized, explorative imaging study evaluating the value of PET as a predictor of histopathological response in metabolic non-responders.
Potential Biases
Potential selection bias due to non-randomized design.
Limitations
The study is not randomized and is exploratory in nature.
Participant Demographics
Patients with resectable AEG type I and II, staged cT3/4 and/or cN+ and cM0.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website